Repeat stool-based screening rates vary widely by health system, study finds by Meg Barbor In a retrospective cohort of nearly 500,000 adults, consistent repeat stool-based screening ranged from 5% to 61% across four health systems and was tied to earlier-stage cancer at diagnosis
Injectable peptides like BPC-157 and TB-500 typically show initial pain relief within 1-2 weeks, with significant improvement by weeks 4-8
Each class has a distinct mechanism, distinct benefits, and distinct risk considerations for the older adult
Constipation typically peaks during the first 24 weeks and gradually improves as your body adjusts over 13 months
In the US, GLP-1 spending rose from $13 to $72 billion in just five years, making approval tough for patients without diabeteseven as data for arthritis risk and cardiovascular benefits grow
Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial
